NAGE on Nasdaq

Niagen Bioscience, Inc.

American medicinal chemicals and botanical products company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Natural Alternatives International, Cronos Group Inc or Mannatech, or pick any stock.

  • TickerNAGE on Nasdaq1
  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersLos Angeles, California1
  • Incorporated inDE2
  • Business address10900 Wilshire Blvd, Suite 600, Los Angeles, Ca 900242
  • Filer categoryLarge accelerated filer2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

On May 21, 2008, Cody Resources, Inc., a Nevada corporation and a public company, (Cody) entered into an Agreement and Plan of Merger (Merger Agreement), by and among Cody, CDI Acquisition, Inc., a California corporation and wholly-owned subsidiary of Cody (Acquisition Sub), and ChromaDex, Inc. (Merger). Subsequent to the signing of the Merger Agreement, Cody merged with and into a Delaware corporation. On June 20, 2008, Cody amended its articles of incorporation to change its name to ChromaDex Corporation. On April 25, 2016, ChromaDex Corporation became listed on the Nasdaq Capital Market (Nasdaq).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

64.3%Gross margin4
12.6%Operating margin4
13.4%Net margin4
29.9%Revenue growth, 20254
22.7%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Consumer Products brought in 75% of the revenue Niagen Bioscience, Inc. broke down this way in fiscal 2025.

  1. Consumer Products$97.7M475%up 27% from 2024
  2. Ingredients$28.7M422%up 45% from 2024
  3. Analytical Reference Standards and Services$3.1M42%up 2% from 2024
Business segments by year
Business segments20242025
Consumer Products$76.8M$97.7M
Ingredients$19.8M$28.7M
Analytical Reference Standards and Services$3.0M$3.1M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue36¢$46.2M
  • Research and development5¢$6.3M
  • Other costs45¢$58.7M
  • Income tax1¢$810.0K
  • Profit13¢$17.4M

Out of $129.4M in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Share buybacks2¢$251.0K
  • Kept or used elsewhere98¢$13.3M

Out of $13.5M of cash from operations.4

Financial statements

Revenue567894$129.4M in 2025+180% since 2019
0$50.0M$100.0M$150.0M2019: $46.3M$46.3M20192020: $59.3M$59.3M2020+28%2021: $67.4M$67.4M2021+14%2022: $72.0M$72.0M2022+7%2023: $83.6M$83.6M2023+16%2024: $99.6M$99.6M2024+19%2025: $129.4M$129.4M2025+30%
Gross profit567894$83.2M in 2025+223% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $25.8M$25.8M20192020: $35.3M$35.3M2020+37%2021: $41.5M$41.5M2021+18%2022: $42.8M$42.8M2022+3%2023: $50.8M$50.8M2023+19%2024: $61.6M$61.6M2024+21%2025: $83.2M$83.2M2025+35%
Operating income567894$16.3M in 2025
-$40.0M-$20.0M0$20.0M2019: -$31.3M-$31.3M20192020: -$19.9M-$19.9M2020−37%2021: -$27.1M-$27.1M2021+36%2022: -$18.6M-$18.6M2022−31%2023: -$5.6M-$5.6M2023−70%2024: $7.7M$7.7M20242025: $16.3M$16.3M2025+111%
Net income567894$17.4M in 2025
-$40.0M-$20.0M0$20.0M2019: -$32.1M-$32.1M20192020: -$19.9M-$19.9M2020−38%2021: -$27.1M-$27.1M2021+36%2022: -$16.5M-$16.5M2022−39%2023: -$4.9M-$4.9M2023−70%2024: $8.6M$8.6M20242025: $17.4M$17.4M2025+103%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Sales, net$129.4M$99.6M
Cost of sales$46.2M$38.0M
Gross profit$83.2M$61.6M
Sales and marketing$35.5M$29.5M
Research and development$6.3M$6.0M
General and administrative$27.1M$18.4M
Gain on settlement of royalty obligation-$2.0M$0
Total operating expenses, net$66.9M$53.9M
Operating income$16.3M$7.7M
Investment Income, Interest$2.1M$1.1M
IRS ERTC disallowance-$214.0K$0
Total nonoperating income, net$1.9M$1.1M
Income before provision for income taxes$18.2M$8.9M
Provision for income taxes$810.0K$305.0K
Net income$17.4M$8.6M
Basic (in dollars per share)$0.22$0.11
Diluted (in dollars per share)$0.20$0.11
Basic (in shares)79.2M shares75.9M shares
Diluted (in shares)85.4M shares78.1M shares

Compare Niagen Bioscience, Inc. with another company

Leadership

Who has led Niagen Bioscience, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Frank L. Jaksch Jr.2008–2018
  2. Jeffrey Himmel2012
  3. Robert N. Fried2018–now

Chair

  1. Frank L. Jaksch Jr.2019–2022

President

  1. Frank L. Jaksch Jr.2008–2016
  2. William Spengler2010–2011
  3. Robert N. Fried2017–2018

Chief financial officer

  1. Thomas C. Varvaro2008–2016
  2. Kevin M. Farr2017–2022
  3. Brianna Gerber2022–2024
  4. Ozan Pamir2024–now

Chief operating officer

  1. Debra Heim2012
  2. Troy Allen Rhonemus2014–2016
  3. Robert N. Fried2018
2010201520202025
Board members and other officers (33)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorGary N. Ng named Oct 14, 202257
  • DirectorSteven N. Rubin named Oct 14, 202257
  • DirectorWendy N. Yu named Oct 14, 202257

Former names

  • ChromaDex Corp.Jun 25, 2008 to Mar 10, 20252
  • CODY RESOURCES, INC.Jan 18, 2007 to Jun 24, 20082

Timeline

  1. Jun 26, 2018New chief executive Robert N. Fried becomes CEO13
  2. Feb 1, 2012New chief executive Jeffrey Himmel becomes CEO14
  3. Jun 25, 2008New chief executive Frank L. Jaksch Jr. becomes CEO15

Filings

215 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 88 insider forms, 14 large holders, 1 private raises, 36 other. The latest 20:

  1. Aug 4, 202610-Q EDGAR
  2. Aug 4, 20268-K EDGAR
  3. Jul 29, 2026SCHEDULE 13G EDGAR
  4. Jul 10, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  5. Jul 9, 2026EFFECT EDGAR
  6. Jul 8, 20264 EDGAR
  7. Jul 8, 20264 EDGAR
  8. Jul 8, 20264 EDGAR
  9. Jun 29, 20268-K EDGAR
  10. Jun 29, 2026S-3 REGISTRATION STATEMENT EDGAR
  11. Jun 26, 20264 EDGAR
  12. Jun 26, 20264 EDGAR
  13. Jun 26, 20264 EDGAR
  14. Jun 26, 20264 EDGAR
  15. Jun 26, 20264 EDGAR
  16. Jun 26, 20264 EDGAR
  17. Jun 26, 20264 EDGAR
  18. May 6, 20268-K EDGAR
  19. May 6, 202610-Q EDGAR
  20. Apr 29, 2026ARS EDGAR

The 215 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 13 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 14, 2025Pamir OzanChief Financial OfficerBuy6,685$6.82$45.6KForm 4
Mar 7, 2025Lopez Carlos LuisSVP, General CounselBuy273$7.86$2.1KForm 4
Dec 13, 2024Jaksch Frank L JrDirectorSale37,161$6.19$230.0KForm 4
Nov 22, 2024Pamir OzanChief Financial OfficerBuy2,907$7.36$21.4KForm 4
Aug 23, 2024Patrick KristinDirectorSale23,000$3.57$82.1KForm 4
Aug 20, 2024Li Ka Shing10% ownerSale11,408,715Form 4
Aug 20, 2024Winsave Resources Ltd10% ownerBuy11,408,715Form 4
Dec 1, 2023Gerber BriannaChief Financial OfficerBuy5,000$1.41$7.0KForm 4
Sep 6, 2023Champion River Ventures Ltd10% ownerBuy3,467,778Form 4
Jun 12, 2023Jaksch Frank L JrDirectorBuy7,000$1.69$11.8KForm 4
May 31, 2023Fried Robert NChief Executive OfficerBuy7,000$1.42$9.9KForm 4
May 25, 2023Rubin Steven DDirectorBuy7,000$1.46$10.2KForm 4
Sep 30, 2022Fried Robert NChief Executive OfficerBuy80,000$1.25$100.0KForm 4
Sep 30, 2022Pioneer Step Holdings Ltd10% ownerBuy960,000$1.25$1.2MForm 4
Jun 16, 2022Chau Hoi Shuen Solina Holly10% ownerBuy60,037$1.66$99.7KForm 4
Mar 16, 2022Fried Robert NChief Executive OfficerBuy25,000$2.16$54.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 30, 2022Raised $3.1 million in a private offering of equity Form D: 3 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.4,184,659$13.3M0.0%+313,040
SteelPeak Wealth, LLC3,500,129$11.2M0.3%+127,129
Vanguard Capital Management LLC2,147,018$6.8M0.0%−2,259
Qube Research & Technologies Ltd1,625,016$5.2M0.0%−89,623
Geode Capital Management, LLC1,478,603$4.7M0.0%+133,682
UBS Group AG1,283,296$4.1M0.0%−122,235
Goldman Sachs Group Inc1,262,743$4.0M0.0%+10,784
Arrowstreet Capital, Limited Partnership1,171,215$3.7M0.0%−1,207,222
Vanguard Portfolio Management LLC1,166,233$3.7M0.0%−55,261
State Street Corp1,082,752$3.5M0.0%−1,813
Renaissance Technologies LLC659,584$2.1M0.0%−669,259
Citadel Advisors LLC630,109$2.0M0.0%+99,632
Dimensional Fund Advisors LP605,326$1.9M0.0%−465,807
Morgan Stanley504,772$1.6M0.0%+123,683
Victory Capital Management Inc473,372$1.5M0.0%+47,950
Aqr Capital Management LLC472,056$1.5M0.0%−559,279
Sei Investments Co471,934$1.5M0.0%−499,640
Northern Trust Corp466,720$1.5M0.0%+70,653
Connor, Clark & Lunn Investment Management Ltd.458,614$1.5M0.0%−123,834
Charles Schwab Investment Management Inc431,614$1.4M0.0%−15,745
Vanguard Fiduciary Trust Co400,253$1.3M0.0%+25,899
Panagora Asset Management Inc347,207$1.1M0.0%+170,197
Jpmorgan Chase & Co333,204$1.1M0.0%+6,493
Jacobs Levy Equity Management, Inc324,690$1.0M0.0%New
Bank Of America Corp /de/291,727$930.6K0.0%−12,991

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66